Regulation of autophagy by microRNAs in human breast cancer

Zhi Xiong Chong1, Swee Keong Yeap2 and Wan Yong Ho1*

Abstract
Breast cancer is the most common solid cancer that affects female population globally. MicroRNAs (miRNAs) are short non-coding RNAs that can regulate post-transcriptional modification of multiple downstream genes. Autophagy is a conserved cellular catabolic activity that aims to provide nutrients and degrade un-useful macromolecules in mammalian cells. A number of in vitro, in vivo and clinical studies have reported that some miRNAs could modulate autophagy activity in human breast cancer cells, and these would influence human breast cancer progression and treatment response. Therefore, this review was aimed to discuss the roles of autophagy-regulating miRNAs in influencing breast cancer development and treatment response. The review would first introduce autophagy types and process, followed by the discussion of the roles of different miRNAs in modulating autophagy in human breast cancer, and to explore how would this miRNA-autophagy regulatory process affect the disease progression or treatment response. Lastly, the potential applications and challenges of utilizing autophagy-regulating miRNAs as breast cancer biomarkers and novel therapeutic agents would be discussed.

Keywords: Breast cancer, miRNAs, Autophagy, Biomarkers, Therapeutic agents

Introduction
Breast cancer is currently the number one cancer that affects the female population worldwide and every year, more than 2 million females will be diagnosed to have this malignancy [1]. It is estimated that more than 40,000 breast cancer patients passed away because of this malignancy in year 2019 alone [2]. The challenge in managing this heterogenous malignancy is that this cancer is highly aggressive [3], and it is always associated with problems like chemoresistance [4], radioresistance [5], resistance towards hormonal therapy [6] and resistance towards targeted therapy [7].

MicroRNAs (miRNAs) are short endogenous, single-stranded, non-coding RNAs (ncRNAs) which contain 18–25 nucleotides [8, 9]. MiRNAs have been reported to play essential roles in regulating the post-transcriptional modification of multiple downstream targets [10]. By binding to the complementary sequences at the 3′-untranslated regions (3′-UTR) of the mRNAs of the target genes, miRNAs could repress the translation of these target genes [11]. With the advancement in the field of molecular biology and clinical science, in the past 20 years, many in vitro, in vivo and clinical studies have been conducted to investigate the potential roles of miRNAs as biomarkers in diagnosing and predicting the prognosis of human breast cancer [12, 13], and, as novel therapeutic agents to tackle breast cancer [14, 15].

Autophagy is a conserved, ubiquitous and important cellular degradative and catabolic activity that aims to maintain cellular homeostasis [16, 17]. This cellular process has been described for more than 30 years ago and it started to gain enormous attention worldwide when Professor Yoshinori Ohsumi was awarded with the Nobel Prize in Medicine and Physiology in year 2016 because of his distinctive works in autophagy [18]. Dysregulation of autophagy has been reported to associate with a number of communicable [19] and non-communicable diseases.
Autophagy-related non-communicable diseases can be further divided into cancerous or non-cancerous diseases like cardiovascular disease [22], neurodegenerative disease [23, 24] and skin disease [25]. Malignancies which are related to autophagy dysregulation include colorectal cancer [21], gastric cancer [26], breast cancer [27, 28], lung cancer [29], leukemia and lymphoma [30], ovarian cancer [31], and few other cancers [32, 33].

Autophagy is essential to provide nutrients to the cancer cells to grow and at the same time, eliminate unusable cellular macromolecules that could potentially pose harm to the cancer cells [34]. From some published in vitro, in vivo and clinical studies’ findings [35–37], regulation of autophagy by miRNAs have been demonstrated to exert some effects in influencing the human breast cancer development and treatment response. In other word, a number of miRNAs was shown to be able to either up- or down-regulate cellular autophagy, and this would eventually enhance or suppress breast cancer progression. This review, therefore, was aimed to summarize the published findings from various studies on the potential roles of miRNAs in regulating autophagy in human breast cancer, and subsequently, to discuss how does this miRNA-autophagy modulation process would influence breast cancer development and treatment response. The review would first introduce autophagy types and process, followed by the discussion on the roles of autophagy-regulating miRNAs in influencing human breast cancer development and treatment response. Lastly, the applications and challenges of employing autophagy-regulating miRNAs as potential breast cancer biomarkers and therapeutic agents would be discussed.

**Autophagy types and process, and functional roles of autophagy in breast cancer**

The main objective of autophagy or “self-eating” (Greek meaning) is to break down cytoplasmic components like macromolecules and organelles, in order to sustain cellular metabolism and to ensure cellular homeostasis [16, 38, 39]. Some people described autophagy as a cellular “re-cycling process” that digests old and unwanted substances and turns it into useful nutrients for cellular usage [25]. Autophagy is important to avoid the accumulation of harmful substances like precipitated proteins, damaged cellular organelles and oncogenic materials that could pose danger to the cells [38, 39]. The failures to eliminate these unnecessary, aged or toxic substances would trigger intracellular inflammation which would generate reactive oxygen species (ROS) and subsequently, these cellular processes would lead to the development of cellular degeneration, apoptosis and carcinogenesis [38–40].

**Types of autophagy**

Autophagy can be generally divided into three types (Fig. 1), namely, macroautophagy, microautophagy and chaperone-mediated autophagy (CMA) [16]. Macroautophagy is an evolutionarily, highly conserved and common type of autophagy that involves the sequestration of a portion of a cellular organelle to form autophagosome [41]. Lysosome then fuses with the autophagosome to form autolysosome in which the macromolecules like proteins and organelles to be degraded will be digested within the autolysosome [39]. Selective macroautophagy is a specific type of autophagy in which selected dysfunctional cellular organelles or substrates will be recognized and selected for autophagy [38]. Examples of selective macroautophagy include mitophagy (mitochondrion), lysophagy (lysosome), pexophagy (peroxisome), ribophagy (ribosome), reticulophagy (endoplasmic reticulum) and nucleophagy (nuclear components) [38]. Microautophagy is a type of autophagy in which multiple, small vesicles are engulfed by the lysosomes via lysosomal cytoplasmic invagination [16]. The detail mechanism of microautophagy in lysosome is still unclear [42] but for endosomal microautophagy, several proteins like endosomal sorting complexes required for transport I and III (ESCRT/III) and heat shock cognate 71 kDa protein (HSC70), have been reported to play essential roles in initiating the electrostatic interaction between the protein substrates and endosomes for autophagy to happen [16]. CMA, on the other hand, is a highly selective process in which the cytoplasmic constituents that are tagged with a special C-terminal KFERQ motif will be recognized by chaperone protein like HSC70, which will then guide them to the lysosome by binding the motif to the lysosome-associated membrane protein type 2a (LAMP-A2) protein on the lysosome surface [43]. LAMP-2A is stabilized by two proteins, namely, GFAP and HSP90 [42]. LAMP-2A monomeric protein must form a multimeric complex to transport the substrate into the lysosome for degradation and this is a dynamic process which involves the monomers assembly for substrate translocation and upon completing the mission, the multimeric complex will be dissociated and degraded [16].

**Autophagy steps**

Next, the molecular mechanism of general autophagy process (Fig. 2) will be discussed. Cellular conditions like nutrients deprivation, presence of oxidative stress or growth hormones and accumulation of senescence organelles will generate autophagy signals to the affected cells [16, 44]. The autophagy process can be generally divided into five stages including initiation, elongation, nucleation, fusion and degradation [39]. This cellular process
will begin at the endoplasmic reticulum (ER) in which part of the double layer membrane of the ER will be bud off to form a cup shape substance called pre-autophagosome (PAS) [45]. A protein complex consists of Unc-51 like autophagy activating kinase (ULK1), autophagy related proteins (Atg13/Atg101) and FAK family kinase-interacting protein of 200 kDa (FIP200) will be recruited and bound to the PAS [46]. This is known as the initiation step of autophagy [46]. The ULK kinase complex phosphorylates and activates autophagy and beclin-1 regulator (AMBRA) protein, and AMBRA then phosphorylates a class III phosphoinositide 3-kinase (PI3K) complex consisting of Beclin1, ATG14L, VPS34 and VPS15 [16]. The activated PI3K complex phosphorylates and activates autophagy and beclin-1 regulator (AMBRA) protein, and AMBRA then phosphorylates a class III phosphoinositide 3-kinase (PI3K) complex consisting of Beclin1, ATG14L, VPS34 and VPS15 [16]. The activated PI3K complex can now convert phosphatidylinositol-4,5-bisphosphate (PIP2) to phosphatidylinositol-3,4,5-bisphosphate (PIP3) [47]. The elevation of the surrounding PIP3 concentration attracts another two proteins called WD repeat domain phosphoinositide-interacting protein (WIPI2) and zinc-finger FYVE domain-containing protein 1 (DFCP1) to the PAS membrane [46]. WIPI2 protein has been reported to play essential roles in binding the ATG16L1 protein and this aids in attracting the ATG16L1/ATG5/ATG12 complex to the PAS [46]. The recruitment of ATG16L1/ATG5/ATG12 complex is important in preventing the premature fusion of the autophagosome with the lysosome [16]. Besides, other proteins which are important in cargo or macromolecules sequestration like p62, sequestosome 1 (SQSTM1) and NBR1 will also be attracted and bind to the PAS [18]. SQSTM1/p62 and NBR1 are important in regulating ubiquitiation processes by facilitating the binding of the selective ubiquitinated proteins to the PAS to be removed via autophagy activity [18]. As different proteins are being recruited and bound to the PAS, it also elongates in preparation for subsequent nucleation process [39].

Once most of the macromolecules, organelles and proteins required for degradation have been recruited, a key protein that aids in the membrane closure called LC3 will come and bind to the membrane of the pre-autophagosome [48, 49]. LC3 is derived from pro-LC3 and the cleavage by cysteine protease ATG4 will produce LC3-1 [50]. ATG3/ATG7 bound complex will then come and facilitate the binding of LC-3 with phosphatidylethanolamine (PE) to form PE-conjugated LC3-II [49]. Together with other autophagy related proteins, PE-conjugated LC3-II will initiate the membrane sealing to form a mature autophagosome [39, 49]. Since LC3-II protein...
is a vital protein involved in the autophagosome formation and nucleation process, the detection of LC3-II has been regarded as one of the usual approaches to measure autophagy activity [39]. Once the membrane of the mature autophagosome is fully formed, LC3-II will be detached and now the autophagosome is ready for fusion with the lysosome [39]. Presence of other proteins like soluble NSF attachment protein receptor (SNARE), lysosome associated membrane protein (LAMP2) and Rab GTPase RAB 7 on the mature autophagosome and lysosome surface will facilitate the fusion with the targeted lysosome to form autolysosome [46, 51]. A number of tethers (HOPS, ATG14L and TECPR1), motor adaptors (FYCO1, PLEKHM1/2 and RILP) will also be involved in mediating the fusion process [51]. As the fusion completes, the autophagosome contents will be released and these substances will be degraded in an acidic environment containing enzymes like cathepsin B, cathepsin L and other hydrolytic enzymes [52, 53]. The digested substances will then be released from the autolysosome via protein channels and it is now can be used for anabolism or other cellular processes [16, 52, 53]. The ultimate fate of the autolysosome, however, is still poorly understood, and it is unclear whether it will dissociate into lysosome and autophagosome after the digestion process is completed [39]. There are a number of proteins which have been proven to play important roles in regulating the cellular autophagy activities [16]. Energy deprivation would raise intracellular adenosine monophosphate-activated protein kinase (AMPK) level and AMPK could phosphorylate ULK1 to activate it while inhibiting tuberous sclerosis 1/2 protein (TSC1/2) to inactivate the mTOR signaling pathway that could block activation of the ULK kinase complex [16, 54]. Protein kinase B or Akt signaling is known to inhibit autophagy induction by activating mTOR and the presence of PTEN will inhibit the PI3K/Akt signaling pathway [55]. As a result, inactivation of the Akt signaling pathway by PTEN will promote autophagy activity [56]. Bcl-2, an important regulating protein of the apoptotic pathway can bind and inhibit Beclin1 to prevent the formation of autophagosome [57]. Endophilin (Bif-1) is
one of the core proteins involved in the vesicle endocytosis and it has been reported to play a vital role in interacting with Beclin-1 to regulate autophagosome formation [58]. Besides, autophagy regulation can also take place at the last phase of autophagy, which is during the autolysosome degradation process [59]. Transcription factor EB (TFEB) and mTOR complex 1 (mTORC1) are two essential proteins in coordinating the lysosome nutrient sensing machinery (LYNUS) of the lysosome [60]. Presence of abundant amino acids inside the lysosome will be sensed by vATPase, a hydrogen pump at the lysosomal membrane surface; and vATPase will relay the information to the rags proteins of the LYNUS complex [60]. When this occurs, mTORC1, which now binds to the LYNUS, will phosphorylate TFEB to inactivate it and prevent it from translocating into the nucleus [60]. Inactivation of TFEB will results in the reduction of the transcription of key genes involved in regulating endocytosis and autophagy, and downregulate the lysosomal biogenesis [59, 60]. This prevents the formation of new autolysosome via fusion of lysosome and autophagosome [60].

Functional roles of autophagy in breast cancer
Like in other human cancer, autophagy could help in either promoting or inhibiting breast cancer [61]. A previous review has reported that autophagy plays a dynamic role in the breast cancer development, and it can be tumour-inhibiting in the early phase of cancer but become tumour-promoting in the later phase of cancer [62]. For tumour-promoting role, autophagy is an important cellular process which helps to provide nutrients and remove harmful cellular macromolecules from the breast cancer cells [63]. Thus, autophagy is said to be playing a vital role in maintaining breast cancer cells homeostasis [63], which in turn could help the cancer cells to survive in stressful conditions like after radiotherapy or targeted therapy have been administered [63, 64]. However, autophagy can be detrimental to the breast cancer cells if it occurs excessively as autophagy is a catabolic cellular process that can lead to cellular death [65]. In some study, it has been reported that autophagy induction can be employed as one of the strategies to accelerate breast cancer cells death and to sensitize the breast cancer cells towards breast cancer therapies like chemotherapy and hormonal therapy [66]. Since autophagy is a complicated cellular process, which its role as a “friend” or “foe” in breast cancer progression is still debatable [65], more functional study is therefore needed to be conducted in the future to determine whether this cellular activity is more likely to promote or inhibit breast cancer development. Clarification of the exact role of autophagy in breast cancer development can help to strategistize beneficial therapeutic options that either induce or inhibit autophagy in breast cancer patients to better eradicate this malignancy from the patients’ body.

Autophagy regulation by miRNAs in human breast cancer: how does this influence disease progression or treatment response
In this review, a total of 41 miRNAs reported from 26 various in vitro, in vivo and clinical studies (Table 1) were included to discuss their roles in regulating autophagy process in human breast cancer development. In general, these autophagy-regulating miRNAs could modulate cellular autophagy (Fig. 3) by regulating (1) autophagy initiation, (2) elongation and nucleation steps moderated by autophagy-related proteins (ATGs), (3) autophagosome formation, and (4) expression of other proteins which do not involve directly in autophagy development. Out of these 41 reported miRNAs, 11 autophagy-regulating miRNAs were further reported to play vital roles in regulating treatment response in breast cancer (Table 2).

Roles of miRNAs in regulating autophagy initiation
Activation of PI3K/Akt/mTOR signaling pathway has been proven to play an essential role in downregulating cellular autophagy activity by activating mTOR protein that suppresses ULK kinase complex activity (Fig. 2) [55]. An in vitro study reported in year 2018 showed that upregulation of miR-486-5p would downregulate PTEN and this resulted in the activation of the PI3K/Akt/mTOR signaling pathway to suppress autophagy and enhance tumorigenesis [56]. PTEN is responsible in dephosphorylating PIP3, an intermediate lipid signaling molecule in the PIP3/Akt/mTOR signaling pathway, and this causes the cessation of signals along this cellular pathway [55].

ULK kinase complex comprises ULK1, ATG13, ATG101 and FIP200 proteins and it is responsible in phosphorylating the downstream Beclin-1 protein to initiate the autophagy activity [49]. In an in vitro study [67] involving triple-negative human breast cancer cell line, MDA-MB-231, the authors reported that 18 miRNAs could play a role in downregulating the signaling hub involving ULK1 and these miRNAs include miR-30c-1, miR-149, miR-611, miR-615-5p, miR-659, miR-636, miR-638, miR-659, miR-675, miR-1303, miR-1308, miR-1908, miR-1914, miR-1915, miR-2861, miR-3184, miR-4292 and miR-4259. Three other miRNAs which were reported to be able to downregulate ULK1 include miR-25 [68], miR-489 [37] and miR-1275 [69]. By suppressing ULK1 expression, these 21 miRNAs could potentially block autophagy induction by reducing the activation of the AMBRA protein, in which AMBRA is important in phosphorylating the downstream Beclin-1 containing class III PI3K [16]. For miR-489, other than being shown to negatively regulate autophagy activity,
| Roles of miRNAs in regulating autophagy and tumorigenesis | miRNAs | Downstream targets (Affected autophagy steps) | Study designs (Data source/cell lines/sample size, n) | Study summary | References |
|----------------------------------------------------------|--------|---------------------------------------------|--------------------------------------------------|--------------|-----------|
| Promote both tumorigenesis and autophagy | miR-23a | XIAP (Indirectly affect autophagy initiation) | In vitro secondary cell lines (MDA-MB-231, MDA-MB-453, T47D, SKBR3, BT546, MCF-10A and MCF-7); in vivo female Balb/c nude mice study (n = unclear for each group) | Overexpression of miR-23a downregulated (p < 0.05) XIAP expression and this promoted autophagy and breast cancer tumorigenesis in vitro and in vivo | [96] |
| | miR-23b-3p | SLC6A14 (Unclassified) | In vitro secondary cell lines (MCF-7, ZR-75-1 and HCC1428); in vivo female Balb/c nude or NSG/NOD mice study (n = 4 for each group) | Downregulation of SLC6A14 by miR-23b-3p caused increased influx of acidic amino acids in the endocrine therapy resistant breast cancer cells and this promoted autophagy and tumorigenesis | [35] |
| | miR-126 | IRS/Glu-4 (Indirectly affect autophagy initiation) | Clinical sampling (breast cancer patients = 106); in vitro secondary cell lines (MCF-7 and MDA-MB-231); in vivo female Balb/c nude mice study (n = 9 for each group) | Overexpression of miR-1.26 downregulated IRS/Glu-4 signaling pathway and activated AMPK/autophagy pathway to promote tumorigenesis | [86] |
| | miR-638 | DACT3 (Autophagosome formation) | In vitro secondary cell lines (KYSE450 ESCC and MCF-7); clinical sampling (breast cancer samples = 24, esophageal cancer tissues = 66) | Upregulation of miR-638 would significantly downregulate (p < 0.05) DACT3 expression, which then promoted autophagy and tumorigenesis in both breast and esophageal cancers | [81] |
| Promote autophagy but suppress tumorigenesis | miR-125b-5p | PAO2 (Indirectly affect autophagy initiation) | In vitro secondary cell lines (MCF-7); in vivo female Balb/c nude mice study (n = 6 for each group) | miR-125b-5p negatively regulated PAO2 (p < 0.05) and this sensitized the breast cancer cells to tamoxifen and docetaxel treatment by accelerating apoptosis and autophagy | [66] |
| Suppress autophagy but promote tumorigenesis | miR-20a | BECN1, ATG16L1, SQSTM1 (Initiation, elongation, maturation and autophagosome formation) | Online clinical data (breast cancer = 694, normal = 83); clinical sampling (n = 30 for cancer or normal tissues); in vitro secondary cell lines (MDA-MB-231 and MCF-7); in vivo female Balb/c nude mice study (n = 12 for each group) | miR-20a level was negatively correlated to BECN1, ATG16L1 and SQSTM1 expression level. Elevated miR-20a increased DNA mutation and tumorigenesis by decreasing autophagy activities | [74] |
| | miR-21 | BECN1, LC3-II (Initiation and autophagosome formation) | In vitro secondary cell line (MCF-7) | Knockdown of miR-21 would enhance autophagy and improve breast cancer cells sensitivity to tamoxifen and fulvestrant by inhibiting PI3K/AKT/mTOR pathway | [75] |
| | miR-25 | ULK1 (Initiation) | In vitro secondary cell lines (MCF-7 and MCF-10A); in vivo female NOD/SCID mice (n = 6 for control or treated group) | Upregulation of miR-25 reduced autophagy by reducing ULK1 expression (p < 0.05). This led to chemoresistance | [68] |
| Roles of miRNAs in regulating autophagy and tumorigenesis | miRNAs | Downstream targets (Affected autophagy steps) | Study designs (Data source/cell lines/sample size, n) | Study summary | References |
|---|---|---|---|---|---|
| Suppress autophagy but promote tumorigenesis | miR-96-5p | LCL-II ↓, FOXO1 ↓, SQSTM1 ↓ (Autophagosomes formation) | In vitro secondary cell lines (MDA-MB-231, MCF-7, BT-549, HS578T, T47D, ZR-75-1 and MCF-10A) | Overexpression of miR-96-5p significantly suppressed (p < 0.05) autophagy and apoptosis, and increased tumorigenesis | [83] |
|  | miR-137 | Pdcd4 ↓ (Indirectly affect autophagy initiation) | In vitro secondary cell lines (SKBR3, MCF-7 and MDA-MB-231) | Overexpression of miR-137 significantly (p < 0.05) apoptosis and autophagy and promoted cancer cells tumorigenesis | [99] |
|  | miR-221 | BECN1 ↓ (Initiation) | In vitro secondary cell lines (MDA-MB-231, MCF-7, T47D, ZR-751, SKBR-3 and HMEC); in vivo athymic female mice (n = 5 for each group) | Elevation of miR-221 downregulated beclin-1 (p < 0.05) in vitro and in vivo. This caused reduced autophagy but increased tumorigenesis and cancer aggressiveness | [76] |
|  | miR-224-5p | Smad4 ↓ (Indirectly affect ATG expression) | Clinical sampling (metastatic breast cancer = 30, non-metastatic breast cancer = 35, normal control = 25); in vitro secondary cell lines (MDA-MB-231 and MCF-7) | Introduction of miR-224-5p suppressed autophagy by reducing Smad4 expression (p < 0.05). High miR-224-5p level was found in metastatic breast cancer patients than normal control or patients with non-metastatic lesions | [101] |
|  | miR-486-5p | PTEN ↓ (Initiation) | In vitro secondary cell lines (MCF-7 and MDA-MB-231) | Upregulation of miR-486-5p would downregulate PTEN expression (p < 0.05) and autophagy but enhanced AKT signaling pathway | [56] |
| Suppress autophagy but promote tumorigenesis | miR-638 | ATG5 ↓, ATG-2B ↓ (Elongation and nucleation) | Case–control (breast cancer or normal control, each had 47 samples), bioinformatics target prediction | Downregulation of miR-638 might be associated with good disease prognosis and slow disease prognosis by increasing autophagy activity | [79] |
| Roles of miRNAs in regulating autophagy and tumorigenesis | miRNAs | Downstream targets (Affected autophagy steps) | Study designs (Data source/cell lines/sample size, n) | Study summary | References |
|----------------------------------------------------------|--------|-----------------------------------------------|-------------------------------------------------|----------------|-----------|
| Suppress both autophagy and tumorigenesis | Let-7a | Un-reported | In vitro secondary cell line (MDA-MB-231) | Overexpression of Let-7a significantly (p < 0.05) increased apoptosis, reduced autophagy, and cell proliferation in vitro | [102] |
| | miR-20a | DRAM1 ↓ (Indirectly affect autophagy initiation) | Clinical sampling (breast cancer tissues and normal tissues = 19); in vitro secondary cell lines (MCF-7, MCF-10A and MDA-MB-231) | Overexpression of miR-20a and miR-20b suppressed (p < 0.05) autophagy and tumorigenesis | [72] |
| | miR-26b | DRAM1 ↓ (Indirectly affect autophagy initiation) | Clinical sampling (breast cancer tissues and normal tissues = 3); in vitro secondary cell line (MCF-7) | Increased expression of miR-26b downregulated DRAM1 protein expression in breast cancer cell and this reduced autophagy and sensitized cancer cells to irradiation | [92] |
| | miR-27a | Lc3-2 ↓ p62 (Autophagosome formation) | In vitro secondary cell lines (MDA-MB-231 and MCF-7) | Introduction of antagonist of miR-27a increased (p < 0.05) LC3-II and p62 expression in vitro, increased autophagy and chemoresistance | [82] |
| Suppress both autophagy and tumorigenesis | miR-101 | STMN1 ↓ RAB5A ↓ ATG4D ↓ (Retection and maturation) | In vitro secondary cell line (MCF-7) | Overexpression of miR-101 downregulated STMN1, RAB5A and ATG4D. This inhibited autophagy and promoted tamoxifen (4-OHT) induced cells apoptosis | [80] |
| | miR-107 | HMGBl ↓ (Initiation) | Clinical sampling (breast cancer patients = 62); in vitro secondary cell lines (MDA-MB-231, MDA-MB-453, MCF-10A and MCF-7); in vivo female Balb/c nude mice study (n = 5 for each group) | In breast cancer tissues and cell lines, miR-107 was downregulated (p < 0.01) and this was associated with increased tumorigenicity. Overexpression of miR-107 downregulated HMGBl in vitro and in vivo and inhibited autophagy | [36] |
| | miR-129-5p | HMGBl ↓ (Initiation) | In vitro secondary cell line (MCF-7) | Upregulation of miR-129-5p significantly suppressed (p < 0.05) HMGBl expression. This led to autophagy downregulation and increased chemosensitivity against taxol | [61] |
| | miR-200c | UQcLN1 ↓ (Autophagosome formation) | Clinical sampling (breast cancer patients = 35); in vitro secondary cell lines (MDA-MB-231, BT549, BT474, MCF-10A and MCF-7) | Ectopic expression of miR-200c downregulated UQcLN1 and this blocked radiation-induced autophagy and sensitized cancer cells to radiotherapy | [93] |
| Suppress both autophagy and tumorigenesis | miR-489 | ULK1 ↓ LAMT4M8 ↓ (Initiation) | In vitro secondary cell line (T47D, MCF-7, MDA-MB-231, MDA-MB-468, MDA-MB-361, HS787T and ZR-75-1); in vivo athymic female mice (n = 5 for each group); clinical sampling (breast cancer patients = 14) | In vitro and in vivo findings suggested that upregulation of miR-489 downregulated ULK1 and LAMT4M8, which then suppressed autophagy and increased cancer cells sensitivity towards doxorubicin | [37] |
Table 1 (continued)

| Roles of miRNAs in regulating autophagy and tumorigenesis | miRNAs | Downstream targets (Affected autophagy steps) | Study designs (Data source/cell lines/sample size, n) | Study summary | References |
|-----------------------------------------------------------|--------|---------------------------------------------|---------------------------------------------------|---------------|------------|
| Suppress both autophagy and tumorigenesis | miR-30c-1 | \( \text{ULK1/2, MAPK3, p62, ATG} \text{upregulated} \) | Clinical sampling divided into 3 cohorts (breast cancer samples \(=161 \), normal tissues \(=127 \)) | Overexpression of miR-1245 would down-regulate \( \text{ULK1/2, ATG7, and ATG5} \) and then suppressed autophagy and tumorigenesis. Downregulation of miR-1275 by circCDYL in breast cancer patients led to poor survival. | [79] |
| | miR-149 | \( \text{ULK1/2, ATG7, ATG5, and nucleation} \) | In vitro secondary cell line (MDA-MB-231) | Introduction of BIK interference would result in the upregulation of a number of autophagy-regulating miRNAs which were shown to regulate several key autophagy-related proteins like ULK1/2, LC3-II and MAPK3 | [67] |
| | miR-611 | \( \text{SNCA} \) | Clinical sampling (breast cancer tissues \(=98 \); in vitro secondary cell lines (SKBR3 and BT474); in vivo male Balb/c nude mice study \(n=4 \) for each group) | Introduction of miR-567 downregulated \( \text{ATG5} \) expression in vitro and in vivo, and this suppressed autophagy and sensitized cancer cells to trastuzumab. | [78] |
| | miR-615-5p | \( \text{SNCA} \) | | | |
| | miR-659 | \( \text{SNCA} \) | | | |
| | miR-636 | | | | |
| | miR-638 | | | | |
| | miR-659 | | | | |
| | miR-675 | | | | |
| | miR-1303 | | | | |
| | miR-1308 | | | | |
| | miR-1908 | | | | |
| | miR-1914 | | | | |
| | miR-1915 | | | | |
| | miR-2861 | | | | |
| | miR-3184 | | | | |
| | miR-4292 | | | | |
| | miR-4259 | | | | |

A total of 41 miRNAs from 26 published in vitro, in vivo and clinical studies were included in this review to discuss their roles in modulating autophagy in human breast cancer and to explore how does this influence the disease development and treatment response. 30 miRNAs were reported to suppress both autophagy and breast cancer tumorigenicity and these include let-7a [102], miR-20a and miR-20b [72], miR-26b [92], miR-27a [82], miR-101 [80], miR-107 [96], miR-129-5p [61], miR-200c [93], miR-489 [37], miR-567 [78], miR-1275 [69], and miR-30c-1, miR-149, miR-611, miR-615-5p, miR-649, miR-659, miR-636, miR-638, miR-659, miR-675, miR-1303, miR-1308, miR-1908, miR-1914, miR-1915, miR-2861, miR-3184, miR-4292 and miR-4259 [67]. Four miRNAs which were shown to enhance both autophagy and breast cancer progression include miR-23a [96], miR-23b-3p [35], miR-126 [86] and miR-638 [81]. Nine miRNAs were found to suppress autophagy but enhance breast cancer development and these miRNAs include miR-20a [74], miR-21 [75], miR-25 [68], miR-96-5p [83], miR-137 [99], miR-221 [78], miR-224-5p [101], miR-486-5p [56] and miR-638 [79]. One miRNA was shown to promote autophagy and suppress breast cancer tumorigenicity and this miRNA is miR-125b-5p [66]. Out of all these miRNAs, miR-20a was found to suppress both autophagy and tumorigenesis in a study [72] but in another study [74], miR-20a was said to promote cancer progression despite it suppressed cellular autophagy. Another miRNA which was shown to have different overall effects on autophagy regulation in breast cancer is miR-638, in which it was demonstrated to accelerate both autophagy and tumorigenesis in a study [81] but in another case-control study [79], miR-638 was shown to inhibit autophagy and promote breast cancer progression.

▲ Upregulation; ▼ Downregulation

Chong et al. J Biomed Sci (2021) 28:21

Page 9 of 18
it was also demonstrated to reduce breast cancer resistance towards doxorubicin in vitro and in vivo [37]. In most of the mentioned studies [37, 67, 69], it was shown that autophagy blockage by the corresponding miRNAs would lead to decreased breast cancer tumorigenesis. However, in the combined in vivo and in vitro study that involved miR-25 [68], it was shown that the introduction of miR-25 mimics would restore cellular proliferation and increase cancer cells resistance towards epirubicin, apart from abrogating autophagy. The opposite effects of autophagy on the breast cancer tumorigenesis suggested that autophagy could play the role of a double-edged sword in promoting cancer progression or suppression [70]. FIP200 is another important component of the ULK kinase complex [71], and this protein was found to be negatively regulated by miR-20a and miR-20b [72]. As a result, suppression of FIP200 by these two miRNAs led to autophagy suppression by blocking autophagy initiation step and this also inhibited cancer progression in vitro [72].

Beclin-1 protein is a key component of the class III PI3K complex which plays an essential role in the autophagy initiation step [16]. Bcl-2 is an anti-apoptotic protein that could bind to Beclin-1 to inactivate it and phosphorylation of Bcl-2 by MAPK/JNK1 would dissociate it from Beclin-1, allowing Beclin-1 to initiate the autophagy signalling activity [73]. Same like the case of ULK1 which has been discussed previously, the in vitro study by Ruiz Esparza-Garrido et al. reported that about 18 miRNAs were found to be able to suppress the signaling hub involving MAPK/JNK1 [67], and thus, this would allow the dephosphorylated Bcl-2 to bind to Beclin-1 to inactivate its activity [73]. Besides, three other miRNAs were shown to negatively regulate Beclin-1 and this include miR-20a [74], miR-21 [75] and miR-221 [76]. Compared to the previous single study that reported 18 potential miRNAs which would suppress Fig. 3 Roles of miRNAs in modulating the autophagy process in human breast cancer. MiR-486-5p is said to downregulate PTEN and this activates PI3K/Akt signaling pathway to inhibit autophagy activity [56]. An in vitro study reported eighteen miRNAs were involved in downregulating the signaling hub which covers ULK1 and these miRNA include miR-30c-1, miR-149, miR-611, miR-615-5p, miR-659, miR-636, miR-638, miR-659, miR-675, miR-1303, miR-1308, miR-1908, miR-1914, miR-1915, miR-2861, miR-3184, miR-4292 and miR-4259 [67]. This group of miRNAs was also found to downregulate the signalling hub which involves Beclin-1 by inhibiting the MAPK/JNK1 signalling pathway [67]. Another five miRNAs were reported to inhibit the ULK kinase complex and these include miR-20a and miR-20b [72], miR-25 [68], miR-489 [37] and miR-1275 [69]. On the other hand, Beclin-1 expression was found to be negatively correlated to the expression of miR-20a [74], miR-21 [75] and miR-221 [76]. MiR-20a could also suppress ATG16L1 expression [74] while miR-567 and miR-638 could negatively regulate ATG5 expression [78, 79]. Overexpression of miR-101 was linked to ATG4 downregulation [80] whereas upregulation of miR-1275 was related to ATG7 suppression [69], and both ATG4 and ATG7 are important in the LC3-II production [16]. Other miRNAs which were involved in suppressing cellular LC3-II production include miR-21 [75], miR-27a [82] and miR-96-5p [83] while miR-638 was found to be involved in promoting LC3-II production [81]. Four miRNAs were reported to be involved in suppressing SQSTM1/p62 expression and these miRNAs include miR-20a [74], miR-27a [82], miR-96-5p [83] and miR-638 [81].
Beclin-1 activity, autophagy and tumorigenicity, these three studies reported enhanced tumorigenicity despite causing autophagy inhibition [74–76]. This suggested that degree of autophagy might influence the survival of cancer cells and excessive autophagy might in fact reduce tumorigenicity [77]. Another possible reason to explain the observation of increase tumorigenicity despite autophagy suppression could be found in one of the studies [75], in which the study discovered that apart from suppressing Beclin-1, miR-21 would also downregulate PTEN to enhance PI3K/Akt signaling pathway. Increase activity of the PI3K/Akt pathway eventually increased tumorigenicity and caused increase resistance of the breast cancer cells towards tamoxifen and fulvestrant in vitro [75]. Therefore, the overall effect on whether an autophagy-regulating miRNA would increase or decrease tumorigenicity also depends on the downstream target or signaling cascade in which it could have exerting effect.

**Table 2** Roles of miRNAs in influencing treatment response in breast cancer by regulating autophagy activities (n = 11)

| Treatment types                  | Influence on treatment response | miRNA(s)     | Autophagy activities (↑, ↓) | Proposed mechanisms/evidences                                                                 | References |
|----------------------------------|---------------------------------|--------------|----------------------------|-----------------------------------------------------------------------------------------------|------------|
| Chemotherapy                     | Resistant-promoting             | miR-25       | ↓                          | miR-25 downregulated ULK1 to suppress autophagy and promote epirubicin resistance in breast cancer cells | [68]       |
|                                  | Sensitivity-promoting           | miR-27a      | ↓                          | miR-27a suppressed LC3-II and p62 expressions to inhibit autophagy and sensitized cancer cells to doxorubicin and paclitaxel | [82]       |
|                                  |                                 | miR-129-5p   | ↓                          | miR-129-5p suppressed HMGB1 to inhibit autophagy and sensitized breast cancer cells to taxol treatment | [61]       |
|                                  |                                 | miR-489      | ↓                          | miR-489 downregulated ULK1 to block autophagy and sensitized breast cancer cells to doxorubicin treatment | [37]       |
| Endocrine therapy                | Resistant-promoting             | miR-23b-3p   | ↑                          | miR-23b-3p downregulated SLC6A14 to promote autophagy and tamoxifen resistance                  | [75]       |
|                                  |                                 | miR-27a      | ↓                          | miR-27a suppressed LC3-II and p62 expressions to inhibit autophagy and sensitize tamoxifen cells to doxorubicin and paclitaxel | [82]       |
|                                  |                                 | miR-101      | ↓                          | miR-101 suppressed ATG4D, STMN1 and RABSA expressions to block autophagy and promote tamoxifen-induced cells death | [80]       |
|                                  |                                 | miR-129-5p   | ↓                          | miR-129-5p suppressed HMGB1 to inhibit autophagy and sensitized breast cancer cells to taxol treatment | [61]       |
|                                  |                                 | miR-489      | ↓                          | miR-489 downregulated ULK1 to block autophagy and sensitized breast cancer cells to doxorubicin treatment | [37]       |
|                                  |                                 | miR-125b-3p  | ↑                          | miR-125b-3p suppressed SLC6A14 to promote tamoxifen resistance                                 | [75]       |
| Endocrine and chemotherapy       | Sensitivity-promoting           | miR-125b-3p  | ↑                          | miR-125b-3p suppressed SLC6A14 to promote both autophagy and apoptosis. This sensitized cancer cells to both tamoxifen and docetaxel | [66]       |
| Radiotherapy                     | Sensitivity-promoting           | miR-26b      | ↓                          | miR-26b downregulated DRAM1 expression to inhibit autophagy and sensitize breast cancer cells to irradiation | [92]       |
|                                  |                                 | miR-200c     | ↓                          | miR-200 downregulated UBQLN1 to block autophagy and sensitized breast cancer cells to irradiation | [93]       |
| Targeted therapy                 | Sensitivity-promoting           | miR-567      | ↓                          | miR-567 suppressed autophagy by downregulating ATG5 to sensitize cancer cells to trastuzumab treatment | [78]       |

11 miRNAs were reported to play essential roles in regulating treatment responses in breast cancer by modulating the cellular autophagy activities [35, 37, 61, 66, 68, 75, 78, 80, 82, 92]. The treatment responses which could be modulated by these autophagy-regulating miRNAs include responses towards chemotherapy [37, 61, 66, 68, 78, 82], endocrine therapy [35, 66, 75, 80], radiotherapy [92, 93] and targeted therapy [78]. Out of these 11 miRNAs, only two miRNAs, namely, miR-23b-3p [75] and miR-125b-3p [66], were shown to upregulate autophagy activities while the rest were demonstrated to inhibit autophagy [35, 37, 61, 68, 78, 80, 82, 92, 93].

↑ Upregulation; ↓ Downregulation

Roles of miRNAs in modulating elongation and nucleation steps during autophagy development by regulating the expression of autophagy-related proteins (ATGs)

Another group of key proteins which play vital roles in modulating autophagy process is the autophagy-related
proteins (ATGs) [49]. A number of miRNAs have been reported to target various ATGs (Fig. 3) and these include miR-20a (ATG16L1) [74], miR-567 and miR-638 (ATG5) [78, 79], miR-101 (ATG4) [80] and miR-1275 (ATG7) [69]. ATG16L1 has been proven to be able to bind to WIP12 protein directly and this helps recruiting the ATG12/ATG15/ATG16L1 protein complex to the pre-autophagosome (PAS) [46]. MiR-21a was found to downregulate ATG16L1 expression and this suppressed autophagy and increased breast cancer carcinogenesis [74]. ATG5, on the other hand, could be negatively regulated by miR-567 [78] and miR-638 [79], and this resulted in autophagy inhibition. In the study which reported the autophagy inhibitory role of miR-567, it was shown that the breast cancer cells showed increased sensitivity towards trastuzumab treatment in vitro following upregulation of miR-567 and thus, this miRNA is said to suppress both autophagy and breast cancer tumorigenicity [78]. However, in the latter case-control study that involved miR-638, it was shown that ATG5 could be negatively regulated by miR-638, but, low miR-638 expression was associated with poor disease prognosis and enhanced disease progression [79]. This suggested that autophagy suppression by miR-638 was linked to increased cancer tumorigenicity [79], and a more detailed mechanistic study is needed to validate this case–control study finding. ATG4 is a cysteine protein which is involved in converting LC3 to LC3-I before LC3-II can be produced [39]. Overexpression of miR-101 would downregulate ATG4 expression, and, this would lead to autophagy and tumorigenicity suppression [80]. In addition, increased expression of miR-101 would also increase the sensitivity of breast cancer cell line, MCF-7, towards tamoxifen treatment, evidenced by increased cells death [80]. Another miRNA that was shown to involve in regulating ATG expression is miR-1275 in which this miRNA has been demonstrated to suppress ATG7 expression, and this resulted in both autophagy and tumorigenicity suppression [69]. ATG7 has been shown to be involved in converting LC3-I to LC3-II by facilitating the covalent binding of LC3-I with phosphatidylethanolamine at the PAS membrane [39]. Therefore, the suppression of ATG7 would affect the LC3-II production and this would affect the formation of mature autophagosome [49].

**Roles of miRNAs in regulating mature autophagosome formation**

On the other hand, several miRNAs were reported to directly regulate the cellular level of LC3-II and miR-638 was shown to directly increase the expression of LC3-II in vitro to increase cellular autophagy and tumorigenesis [81]. This study finding contradicts another study finding which stated that miR-638 was involved in downregulating autophagy by targeting ATG5 and ATG-2B [79]. In another study [67], upregulation of miR-638 was found to enhance cellular LC3-II level, but, the authors described that this phenomenon could be related to other stimulus induction as most of the autophagy-related transcripts were downregulated when miR-638 expression was increased. Therefore, more functional assay may need to be conducted to clarify the exact role of miR-638 in regulating cellular autophagy and tumorigenesis. For miRNAs that were shown to correlate to decreased cellular LC3-II level, three miRNAs were reported and these include miR-21 [75], miR-27a [82] and miR-96-5p [83]. For miR-21, apart from being demonstrated to decrease cellular LC3-II level, miR-21 was also shown to suppress Beclin-1 expression and these combined effects would inhibit autophagy in vitro [75]. The upregulation of both miR-27a and miR-96-5p were proven to reduce cellular level of LC3-II to suppress autophagy and tumorigenesis [82, 83]. In addition, overexpression of miR-27a was also shown to improve the breast cancer cells sensitivity towards doxorubicin and paclitaxel in vitro [82]. Besides, both miR-27a and miR-96-5p were proven to reduce the cellular level of SQSTM1 protein in vitro [82, 83]. SQSTM1 is an important ubiquitination protein that tags the macromolecules or cargo to be degraded so that these substances can be recognized and bind to the autophagy initiating complex [18]. Downregulation of SQSTM1 would impair substrates delivery to the autophagosome and this would result in the accumulation of aggregated protein and thus, this would eventually lead to inflammatory and degenerative disease [18]. Other miRNA which was shown to suppress cellular SQSTM1 includes miR-20a and this miRNA also downregulates other autophagy related proteins like ATG16L1 and Beclin 1 [74].

Even though multiple miRNAs have been reported to play essential roles in regulating autophagy initiation, elongation, nucleation and autophagosome formation, however, to the best of our knowledge, there is a lack of study which has reported any miRNA that could target the key proteins (LAMP2, SNARE, Rab GTPase RAB7) which are important in regulating the fusion of autophagosome and lysosome to form autolysosome.

**Roles of miRNAs in regulating autophagy by modulating expressions of other proteins that do not involve directly in autophagy development**

Apart from regulating the key proteins involved in the autophagy signaling pathway (Fig. 3), there are also some miRNAs which could modulate the autophagy activities by regulating other cellular proteins which are not involved directly in the autophagy signaling pathway. SLC6A14 is a type of basic amino acid transporter that
is negatively regulated by miR-23b-3p and the downregulation of this transporter would result in the increased influx of acidic amino acids via another transporter, SLC1A2 [35]. The disruption in the cellular amino acid level may promote autophagy [84] and SLC6A14 blockage has been shown to promote autophagy in colon cancer [85]. As a result, miR-23b-3p was shown to enhance both autophagy and tumorigenesis, and increase resistance of the breast cancer cells towards hormonal drugs like fulvestrant and tamoxifen [35]. MiR-126 was reported to downregulate the IRS/OGC-4 signaling pathway and this would cause cellular energy deprivation [86]. It has been widely established that glucose depletion is an essential factor that triggers autophagy [87] and thus, miR-126 is said to induce autophagy by activating the AMPK/autophagy signaling cascade [86]. PAD2 is a corepressor of tumour suppressor p53 protein [88] and p53 can negatively regulate PI3K/Akt signaling pathway [89]. MiR-125b-5p was reported to downregulate PAD2 and this would increase p53 expression that inhibits PI3K/Akt signaling [66]. Blockage of PI3K/Akt signaling pathway would enhance autophagy as mTOR is downregulated and the net effect was increased autophagy, decreased cancer cells proliferation and increased cancer cells sensitivity towards tamoxifen and docetaxel [66]. HMGB1 is an autophagy-regulating protein that functions to displace Bcl-2 to bind to Beclin-1, in order to activate Beclin-1 for autophagy induction [90]. An in vivo study involving MCF-7 cancer cell line showed that overexpression of miR-129-5p would downregulate HMGB1 and therefore, this suppressed both autophagy and tumorigenesis [61]. In addition, upregulation of miR-129-5p was also found to improve MCF-7 sensitivity towards taxol in vitro [61]. Another mRNA which was reported to downregulate HMGB1 is miR-107 [36] and like miR-129-5p, miR-107 suppressed both autophagy and cancer cells proliferation by downregulating HMGB1 expression.

DRAM1 is identified as a direct downstream target of p53 and its detailed role in autophagy modulation is still not fully understood [91]. DRAM1 may be involved in increasing lysosomal acidification or inhibiting Akt signaling pathway to promote cellular autophagy [91]. In a combined clinical and in vitro study [92], it was shown that overexpression of miR-26b would negatively regulate DRAM1 expression and this resulted in decreased autophagy, tumorigenesis and improved cancer cells sensitivity towards radiotherapy. In another combined clinical and in vitro study [93], ectopic expression of miR-200c was shown to downregulate UBQLN1 to suppress autophagy and tumorigenesis, and sensitized the breast cancer cells towards radiotherapy. UBQLN proteins like UBQLN1 and UBQLN4 have been reported to play some roles during the formation of autophagosome and these proteins might also help in the fusion of autophagosome and lysosome to form autolysosome [94]. XIAP is an anti-apoptotic protein in which its role in autophagy modulation remains controversy [95]. MiR-23a was reported to downregulate XIAP to increase autophagy and tumorigenesis in a published study finding [96], however, the exact molecular mechanism on how XIAP downregulation led to enhanced autophagy was not explored further. One possible explanation is that XIAP might play certain role in inhibiting MDM2/p53 signaling pathway to block autophagy induction [95] and by suppressing XIAP expression, autophagy could be induced [96].

Fundc1 is an important mammalian mitochondrial membrane protein which plays an essential role in recruiting LC3 to the mitochondrion to initiate mitophagy [97]. It has been reported that Fundc1 could also upregulate the expression of autophagy-related proteins like Beclin-1, ATG5 and ATG7, and apoptotic-related proteins like BAX [98]. In view of the multiple autophagy roles that could be played by Fundc1 protein, a group of researchers investigated the potential role of miR-137 in modulating Fundc1 expression and they found that this protein could be negatively regulated by miR-137 [99]. Downregulation of Fundc1 following miR-137 overexpression would subsequently promote tumorigenesis [99] and the reason of increased tumorigenesis could be related to the downregulation of the apoptotic-related genes following Fundc1 downregulation [98]. Another protein which has been reported to be involved in regulating the transcription of autophagy-related genes is Smad4 and it is part of the TGF-β regulated signaling pathway [100]. The activation of the TGF-β/Smad4 signaling pathway will increase the expression of several key autophagy-related proteins like ATG5, ATG6 and ATG7 [100]. MiR-224-5p was reported to suppress Smad4 expression and autophagy in vitro and this resulted in increased cancer cells tumorigenicity [101]. Like Fundc1, Smad4 also involves in upregulating expression of apoptotic-related proteins like Bcl, BIK and BIM [100] and thus, suppression of Smad4 would lead to apoptosis inhibition and cause increase in the cancer progression [101]. Let-7a, on the other hand, was reported to downregulate both autophagy and cancer cells tumorigenesis in vitro but its direct downstream target was unreported [102]. However, let-7a has been reported to promote autophagy in other solid cancers like gastric cancer [26] and lung cancer [29]. Therefore,
more study is needed to confirm whether let-7a would suppress autophagy in human breast cancer cells.

Roles of autophagy-regulating miRNAs in modulating treatment response in breast cancer

From all the previously discussed autophagy-regulating miRNAs, 11 miRNAs were further reported to be involved in regulating treatment responses towards chemotherapy [37, 61, 66, 68, 82], endocrine therapy [35, 66, 75, 80], radiotherapy [92, 93] and targeted therapy [78] in breast cancer (Table 2). Four miRNAs, namely, miR-25, miR-27a, miR-129-5p and miR-489 were reported to suppress autophagy in breast cancer cells [37, 61, 68, 82]. However, miR-25 was the only miRNA which was demonstrated to promote chemoresistant in breast cancer [68] while the other three miRNAs were proven to promote chemosensitivity in breast cancer [37, 61, 82]. As autophagy has been reported to be able to exert both tumour-promoting and tumour-suppressing effects [61], it is therefore not surprising that autophagy induction or inhibition would promote treatment resistance in some study while in other study, autophagy dysregulation could promote sensitivity towards a specific cancer therapy. Similar phenomenon was observed when it was shown that both miR-21 and miR-101 would suppress cellular autophagy activities but the former miRNA would promote resistance towards endocrine therapy [35] while the latter one would promote sensitivity towards endocrine therapy [80]. Compared to miR-21 and miR-101, miR-23b-3p was the only miRNA which was shown to promote both autophagy and resistance towards endocrine therapy in breast cancer [75]. Other than miRNA, other non-coding RNAs like long non-coding RNA H19 has also been reported to be able to promote both autophagy and tamoxifen resistance in breast cancer [103]. On the other hand, miR-125b-5p was recognized as the autophagy-promoting miRNA that could induce sensitivity towards both chemotherapy and hormonal therapy by upregulating cellular autophagy and apoptosis [66]. This suggests that miR-125b-5p could be possibly further studied to investigate its potential to be used in clinical trial to improve sensitivity of the breast cancer patients towards both chemotherapy and endocrine therapy.

For radiotherapy, miR-26b and miR-200c were reported to be autophagy-inhibiting miRNAs that promote radiosensitivity [92, 93]. These findings probably suggested that autophagy could be important in providing nutrients for the cancer cells to maintain cellular homeostasis during radiotherapy [63]. Similarly, miR-567 was also shown to suppress autophagy and promote sensitivity towards targeted therapy in breast cancer [78]. Again, this further supported the essential role of autophagy in ensuring the cancer cells survival when targeted therapy is administered [64]. One important point to take note of is that it can be observed that autophagy induction or inhibition in chemotherapy and endocrine therapy could either promote treatment resistance or treatment sensitivity but in both radiotherapy and targeted therapy, autophagy inhibition seems to promote treatment sensitivity only than treatment resistance.

Autophagy-regulating miRNAs as potential breast cancer biomarkers and therapeutic agents: applications, challenges and recommendations

As discussed in the previous section, it can be clearly seen that a number of miRNAs (Table 1) has been demonstrated to influence the breast cancer progression or treatment response by modulating the cellular autophagy process. By understanding the relationships between a specific miRNA and its effect on the cellular autophagy modulation and tumorigenesis, it helps enabling this miRNA to be employed as the breast cancer biomarker [37, 79]. Take miR-125b-5p as an example, upregulation of this miRNA would suppress breast cancer tumorigenesis and sensitize the breast cancer cells towards tamoxifen and docetaxel by accelerating both apoptosis and autophagy [66]. The autophagy enhancement was achieved by downregulating PAD2 protein expression [66] and this protein is a corepressor for tumour suppressor protein p53 [88]. Therefore, by monitoring the level of miR-125b-5p in the human breast cancer patients, it may help to monitor the disease progression and predict the response towards hormonal and chemotherapy. Besides, miRNA can also be utilized as a novel therapeutic agent to tackle breast cancer progression [35, 99]. For instance, miR-107 has been proven to inhibit breast cancer cells proliferation, migration and autophagy in vivo and in vitro by targeting HMGB1 [36]. This generates a possibly to increase the expression of miR-107 level in the human breast cancer patients to slow breast cancer progression [36]. In short, the use of miRNAs as cancer biomarkers and therapeutic agents may help allow disease detection and progress monitoring, which will then help the patients to improve their treatment response and survival [104].

Autophagy can be a double-edged sword in either promoting cancer progression or suppression [61, 70]. Autophagy may help generating nutrients for the cancer cells to grow and remove dysfunctional cellular macromolecules but excessive autophagy may lead to cellular death [55, 77]. Even though numerous studies have proposed the potential roles of autophagy-regulating miRNAs as cancer biomarkers or therapeutic agents, one problem faced is that some autophagy-regulating miRNA seems to exert different effects on the breast cancer tumorigenesis in different studies. By taking miR-20a as an
example, in the study reported by Liu et al., it was shown that miR-20a would suppress autophagy but enhance breast cancer progression in vivo and in vitro [74]. However, in another study, it was demonstrated that miR-20a would suppress both autophagy and breast cancer progression [72]. Both studies reported autophagy suppression by miR-20a but this miRNA would exert different effects on the breast cancer tumorigenesis in two different studies [72, 74]. Therefore, it is inconclusive to say whether miR-20a upregulation in the breast cancer patient is a good or bad sign and thus, more further study is needed to validate the exact role of miR-20a clinically, before this miRNA can be used as a breast cancer biomarker or therapeutic agent.

Another problem with the potential use of miRNAs as cancer biomarker is that it requires many detailed and independent testings, before a panel of effective and specific cancer biomarkers can be introduced [105]. To the best of our knowledge, currently there is no a panel of autophagy-regulating miRNAs which has gone through multiple testings to prove its effectiveness and specificity. So, it is suggested that future study can focus on the list of autophagy-regulating miRNAs which have been reported to play roles in human breast cancer development, and from the list, more detailed study can be conducted to evaluate the suitability of these miRNAs as breast cancer biomarkers. As for the use of miRNA as potential cancer therapeutic agent, several problems like suitable delivery methods and unwanted off-target effects are still remain unsolved [106], and thus, there is still a long way to go before autophagy-regulating miRNAs can be certified safe to be employed as the novel breast cancer therapeutic agent.

Conclusions
This review effectively summarizes the findings from various in vitro, in vivo and clinical studies on the roles of a number of autophagy-regulating miRNAs in influencing the human breast cancer progression and treatment response. By modulating the cellular autophagy process, these miRNAs could actually suppress or enhance the breast cancer progression. Therefore, these miRNAs have great potentials to be developed into useful breast cancer biomarkers or new therapeutic agent. To make this happens, more detailed mechanistic and clinical trials should be conducted to evaluate the safety, specificity, sensitivity and effectiveness of these miRNAs as breast cancer biomarkers and therapeutic agents.

Abbreviations
ATG4D: Autophagy related 4D cysteine peptidase; BAX: Bcl-2-associated X protein; Bcl-2: B cell lymphoma 2; BECN1: Beclin-1; Bif-1: Endoplasmic, BIK: Bcl-2 interacting killer protein; BIM: Bcl-2 like protein 11; CMA: Chaperon-mediated autophagy; DACT3: Dishevelled binding antagonist of beta catenin 3; DFCP1: Zinc-finger FYVE-domain-containing protein 1; DRAM1: DNA damage-regulated autophagy modulator protein 1; ER: Endoplasmic reticulum; ESCRT/III: Endosomal sorting complexes required for transport I and III; FIP200: FAK family kinase-interacting protein of 200 kDa; FOXO1: Forkhead box protein O1; Fundc1: FUN14 domain-containing protein 1; FYN1: FYVE and coiled-coil domain-containing protein 1; GRAP: Gial fibrillary acidic protein; Glut-4: Glucose transporter type 4; HGS: Hepatocyte growth factor-regulated tyrosine kinase substrate; HKG1: High mobility group box 1 protein; HOPS: Homotypic fusion and protein sorting protein complex; HSC70: Heat shock cognate 71 kDa protein; HSP90: Heat shock protein 90; IRS: Insulin receptor substrate; JNK1: c-Jun N-terminal kinase 1; LAMN-A2: Lysosome-associated membrane protein type 2a; LAPTMB4: Lysosomal protein transmembrane 4 beta; LC3-II: LC3-phosphatidylethanolamine conjugate IV; LKB1: Serine/threonine-protein kinase STK11; LYN: Lysosome nutrient sensing machinery; MAPK: Mitogen activated protein kinase; MDA2: Mouse double minute 2 homolog; MiRNA: MicroRNA; MRNA: Messenger RNA; MTR: Mammalian target of rapamycin; NR1B1: Next to BRCA1 gene 1 protein; ncRNA: Non-coding RNA; NBR1: Next to BRCA1 gene 1 protein; NOD: Non-obese diabetic; PAD2: Peptidylarginine deiminase 2; PAS: Pre-autophagosome protein; PHTF: Phosphatidylinositolphospholipid; PI3K: Phosphoinositide 3-kinase; PIP2: Phosphatidylinositol-4,5-bisphosphate; PIP3: Phosphatidylinositol-3,4,5-bisphosphate; PKH/Akt: Protein kinase B; PLEKHM1/2: Pleckstrin homology domain-containing family M member 1/2; PML: Promyelocytic leukemia protein; PTEN: Phosphatase and tensin homolog; RABSA: Ras-related protein Rab-5A; RBC1: RB1-inducible coiled-coil protein 1; RILP: Rab-interacting lysosomal protein; RNA: Ribonucleic acid; RTK: Receptor tyrosine kinase; SCID: Severe combined immunodeficiency disease; SLC6A14: Sodium- and chloride-dependent neutral and basic amino acid transporter B; Smad4: Smad family member 4; SNARE: Soluble NSF attachment protein receptor; SNCA: α-Synuclein; SQSTM1: Sequestosome-1; STMN1: Stathmin 1; TECPR1: Tectonin beta-propeller repeat containing 1; TFB1M: Transcription factor EB; TGF-β: Transforming growth factor β; TSC1/2: Tuberous sclerosis 1/2; UBQLN1: Ubiquilin-1; ULK1: Unc-51 like autophagy activating kinase; VPS15/34: Vacular protein sorting 15/34; WIPI2: WD repeat domain phosphoinositide-interacting protein 2; XIAP: X-linked inhibitor of apoptosis protein; 3′-UTR: 3′-Untranslated region; 4-OHT: 4-hydroxatamoxifen.

Acknowledgements
Zhi Xiong Chong received scholarship from University of Nottingham Malaysia. Authors wish to thanks MOHE, Malaysia for funding this study.

Authors’ contributions
WYH and SKY conceptualized the idea, developed the structure of the article and guided the selection of references, ZXC prepared the figures/Table. All authors read and approved the final manuscript.

Funding
This work was supported by FRGS grant by Ministry of Higher Education, Malaysia, Grant number FRGS/1/2018/STG05/UNIM/02/1 and FRGS/1/2014/SG05/UNIM/02/1.

Availability of supporting data
All data was included in the manuscript.

Declarations
Ethics approval and consent to participate
Not applicable.
Consent for publication
Not applicable.
Competing interests
The authors report no conflict of interest.
References

1. World Health Organizations. Human breast cancer. 2020. https://www.who.int/cancer/prevention/diagnosis-screening/breast-cancer/en/. Accessed 8 Mar 2020.

2. American Cancer Society. Breast cancer facts and figs. 2019–2020. Am Cancer Soc. 2020. https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/breast-cancer-facts-and-figures/breast-cancer-facts-and-figures-2019-2020.pdf. Accessed 24 Oct 2020.

3. Januškevičienė I, Petrikaitė V. Heterogeneity of breast cancer: The importance of interaction between different tumor cell populations. Life Sci. 2019;239:117009. https://doi.org/10.1016/j.lfs.2019.117009.

4. JI X, Lu Y, Tian H, Meng X, Wei M, Cho WC. Chemoresistance mechanisms of breast cancer and their countermeasures. Biomed Pharmacother. 2019;114:108800.

5. Gray M, Turnbull AK, Ward C, Meehan J, Martinez-Perez C, Bonello M, et al. Development and characterisation of acquired radioresistant breast cancer cell lines. Radiat Oncol. 2019;14:64.

6. Fan W, Chang J, Fu P. Endocrine therapy resistance in breast cancer: current status, possible mechanisms and overcoming strategies. Front Med Chem. 2015;7:1511–9.

7. Denakhchani A, Rezaei Z, Safarpour H, Sabri M, Mir A, Sanati MA, et al. Overcoming trastuzumab resistance in HER2-positive breast cancer using combination therapy. J Cell Physiol. 2020;235:3142–56.

8. Yu Y, Cao XC. MRI-190–5p in human diseases. Cancer Cell Int. 2019;19:257. https://doi.org/10.1186/s12935-019-0984-x.

9. Loh H-Y, Norman BP, Lai K-S, Rahman NMANA, Alitheen NBM, Osman MA. The regulatory role of microRNAs in breast cancer. Int J Mol Sci. 2019;20:4940.

10. Brien JO, Hayder H, Zayed Y, Peng C. Overview of microRNA biogenesis, mechanisms of actions, and circulation. Front Endocrinol (Lausanne). 2018;9:402.

11. Mayya VK, Duchaine TF. Ciphers and executioners: how 3 prime-untranslated regions determine the fate of messenger RNAs. Front Genet. 2019;10:166.

12. Hamam R, Hamam D, Alsaleh KA, Kassem M, Zaher W, Alfarayeen MA, et al. Circulating microRNAs in breast cancer: novel diagnostic and prognostic biomarkers. Cell Death Dis. 2017;8:e3045. https://doi.org/10.1038/cddis.2017.440.

13. Rehman Q, Zhuang H, Ali AM, Ibrahim A, Li Z. Validation of miRNAs as breast cancer biomarkers with a machine learning approach. Cancers (Basel). 2019;11:4311.

14. Behgoura A, Akouchekian M. Therapeutic impacts of microRNAs in breast cancer by their roles in regulating processes involved in this disease. J Res Med Sci. 2017;22:130.

15. Hanna J, Hossain GS, Koceriha J. The potential for microRNA therapeutics and clinical research. Front Genet. 2019;10:478.

16. Khandal R, Dadar M, Munjal A, Tiwari KOKR, Yatoo MI, Igbal HW, et al. A comprehensive review of autophagy and its various roles in infectious, non-infectious, and lifestyle diseases: current knowledge and prospects for disease prevention, novel drug design, and therapy. Cells. 2019;8:674.

17. Flynn ALB, Schiemann WP. Autophagy in breast cancer metastatic dormancy: tumor suppressing or tumor promoting functions? J Cancer Metastasis Treat. 2019;5:43.

18. Kirkin V. History of the selective autophagy research: how did it begin and where does it stand today? J Mol Biol. 2020;432:3–27. https://doi.org/10.1016/j.jmb.2019.05.010.

19. Kim YS, Silwal P, Kim SY, Yoshimori T, Jo EK. Autophagy-activating strategies to promote innate defense against mycobacteria. Exp Mol Med. 2019;51:151. https://10.1038/s41276-019-0290-7.

20. Xiong H, Shen J, Chen Z, Yang J, Xia B, Jia Y, et al. H19/let-7/林28 cell RNA network mediates autophagy inhibiting epithelial-mesenchymal transition in breast cancer. Int J Oncol. 2020;56:794–806.

21. Devenport SN, Shah YM. Functions and implications of autophagy in colon cancer. Cells. 2019;8:1349.

22. Abdelzafar M, Sedej S, Carmona-Gutierrez D, Madeo F, Kroemer G. Autophagy in cardiovascular aging. Circ Res. 2018;123:803–24.

23. Chen H-X, Liang F-C, Gu P, Xu B-L, Xu H-J, Wang W-T, et al. Exosomes derived from mesenchymal stem cells repair a Parkinson’s disease model by inducing autophagy. Cell Death Dis. 2020;11:288. https://doi.org/10.1038/s41419-020-2475-z.

24. Uddin MS, Stachowiak A, Al Mamun A, Tzvetkov NT, Takeda S, Atanason AG, et al. Autophagy and Alzheimer’s disease: from molecular mechanisms to therapeutic implications. Front Aging Neurosci. 2018;10:104.

25. Guo Y, Zhang X, Wu T, Hu X, Su J, Chen X. Autophagy in skin diseases. Dermatol. 2019;235:380–9.

26. Fan H, Jiang M, Li B, He Y, Huang C, Luo D, et al. MicroRNA-let-7a regulates cell autophagy by targeting Rictor in gastric cancer cell lines. MGC-803 and SGC-7901. Oncol Rep. 2018;39:1207–14.

27. Gu J, Wang Y, Wang X, Zhou D, Wang X, Zhou M, et al. Effect of the IncRNA GASS-mir-23a-ATG3 axis in regulating autophagy in patients with breast cancer. Cell Physiol Biochem. 2018;48:194–207.

28. Xu S, Wang P, Zhang J, Wu H, Su S, Zhang J, et al. Al-IncRNA EGT enhances autophagy sensitivity to paclitaxel cytotoxicity via upregulation of the PTEN expression by RNA-RNA and RNA-protein interactions in human breast cancer. Mol Cancer. 2019;18:89.

29. Duan S, Yu S, Yuan T, Yao S, Zhang L. Exogenous let-7a-5p induces A549 lung cancer cell death through BCL2L1-mediated PI3K/Akt signaling pathway. Front Oncol. 2019;9:808.

30. Dijavanen-Mergny M, Giuriato S, Tchan MP, Humbert M. Therapeutic modulation of autophagy in leukemia and lymphoma. Cells. 2019;8:103.

31. Gan X, Zhu H, Jiang X, Obiegbusi SC, Yong M, Long X, et al. CirciMUC16 promotes epithelial of ovarian cancer via interaction with ATG13 and mTOR-199a. Mol Cancer. 2020;19:495.

32. Fazio P, Di Matrood S. Targeting autophagy in liver cancer. Transl Gastroenterol Hepatol. 2018;3:39.

33. Amaravadi RK, Kimmelman AC, Debnath J. Targeting autophagy in cancer: recent advances and future directions. Cancer Discov. 2019;9:1167–81.

34. Yun CW, Lee SH. The roles of autophagy in cancer. Int J Mol Sci. 2018;19:3466.

35. Bacci M, Lorno N, Ippolito L, Ramazzotti M, Luti S, Romagnoli S, et al. Reprogramming of amino acid transporters to support aspartate and glutamate dependency sustains endocrine resistance in breast cancer. Cell Rep. 2019;28:104–18.e8.

36. Ai H, Zhou W, Wang Z, Qiong G, Chen Z, Deng S. microRNAs-107 inhibited autophagy, proliferation, and migration of breast cancer cells by targeting HMGB1. J Cell Biochem. 2019;120:8696–705.

37. Soni M, Patel Y, Markoutsa E, Jie C, Liu S, Xu P, et al. Autophagy, cell viability and chemo-resistance are regulated by miR-489 in breast cancer. Mol Cancer Res. 2018;16:1348–60.

38. Yao R-Q, Ren C, Xia Z-F, Yao Y-M. Organelle-specific autophagy in inflammatory diseases: a potential therapeutic target underlying the quality control of multiple organelles. Autophagy. 2020;12:1–17. https://doi.org/10.1002/aut.235377.

39. Acevedo-rodrguez PS, Maldonado G, Castro-obregón S, Hernandez G. Autophagy regulation by the translation machinery and its implications in cancer. Front Oncol. 2020;10:322.

40. Tompkins KD, Thurburn A. Regulation of apoptosis by autophagy to enhance cancer therapy. Yale J Biol Med. 2019;92:707–18.

41. Gouzoulic D, Akkoc Y, Gulfem Czturk D, Kocak M. Autophagy-regulating microRNAs and cancer. Front Oncol. 2017;7:65.

42. Yim WW, Mizushima N. Lysosome biology in autophagy. Cell Discov. 2020;6:6. https://doi.org/10.1038/s41421-020-0141-7.

43. Dong S, Aguirre-Hernandez C, Scivo A, Elsichov C, Arias E, Bravo-Cordero JJ, et al. Monitoring spatiotemporal changes in chaperone-mediated autophagy in vivo. Nat Commun. 2020;11:645.

44. Slobodynyuk K, Radic N, Ivanova S, Llado A, Trepolec N, Zorzano A, et al. Autophagy-induced senescence is regulated by p38alpha signaling. Cell Death Dis. 2019;10:376.
45. Kotani T, Kiisuzi H, Kozumai M, Ohsumi Y, Nakatogawa H. The Atg2-Atg18 complex tethers pre-autophagosomal membranes to the endoplasmic reticulum for autophagosome formation. Proc Natl Acad Sci USA. 2018;115:10365-8.

46. Dikic I, Elazar Z. Mechanism and medical implications of mammalian autophagy. Nat Rev Mol Cell Biol. 2018;19:349-64. https://doi.org/10.1038/s41580-018-0003-4.

47. Li F, Guo H, Yang Y, Feng M, Liu B, Ren X, et al. Autophagy modulation in bladder cancer development and treatment (Review). Oncol Lett. 2019;42:1647–55.

48. Graef M. Recent advances in the understanding of autophagosome biogenesis. F1000 Res. 2020;9:F1000 Faculty Rev-212.

49. Li X, He S, Ma B. Autophagy and autophagy-related proteins in cancer. Mol Cancer. 2020;19:12.

50. Agrotis A, Chamier L, Von, Oliver H, Kiso K, Singh T, Ketteler R. Human ATG4 autophagy proteases counteract attachment of ubiquitin-like LC3/GABARAP proteins to other cellular proteins. J Biol Chem. 2019;294:12610–21.

51. Lorincz P, Juhasz G. Autophagosome-lysosome fusion. J Mol Biol. 2019;2019:5637075.

52. Voisin A, Monville C, Plancheron A, Béré E, Gaillard A, Leveziel N. Catheter. Mol Cancer. 2020;19:12.

53. Li J, Balboula AZ, Aboelenain M, Fujii T, Moriyasu S, Bai H, et al. Effect of autophagy induction and cathepsin B inhibition on development of colorectal competence of poor quality bovine oocytes. J Reprod Dev. 2020;66:83–91.

54. Holzner M, Hajduš B, Lorincz T, Szarka A, Bánhegyi G, Kapuy O. A double negative feedback loop between mTORC1 and AMPK kinases guarantees precise autophagy induction upon cellular stress. Int J Mol Sci. 2019;20:5543.

55. Heras-Sandoval D, Pérez-Rojas JM, Hernández-Damián J, Pedraza-Sanchez A, Bascón A, et al. Role of miR-20a and miR-20b negatively regulate autophagy by targeting RBR1C1/FIP200 in breast cancer cells. Life Sci. 2016;147:143–52. https://doi.org/10.1016/j.lfs.2016.01.044.

56. Zhou YY, Li Y, Jiang WQ, Zhou LF. MAPK/JNK signalling: a potential autophagy regulation pathway. Biosci Rep. 2015;35:e00199.

57. Liu L, He J, Wei X, Wan G, Lao Y, Xu W, et al. MicroRNA-20a-mediated loss of autophagy contributes to breast tumorogenesis by promoting genomic damage and instability. Oncogene. 2017;36:5674–84.

58. Yu X, Li R, Shi W, Jiang T, Wang Y, Li C, et al. Silencing of MicroRNA-21 confers the sensitivity to taxol and fulvestrant by enhancing autophagic cell death through inhibition of the PI3K-AKT-mTOR pathway in breast cancer cells. Biomed Pharmacother. 2016;77:37–44. https://doi.org/10.1016/j.biopha.2015.11.005.

59. Pradhan AK, Talukdar S, Bhoopathi P, Shen X-N, Emdad L, Das SK, et al. miR-7-5p-24 mediates cancer cell-specific death via regulation of miR-221 and the beclin-1 axis. Cancer Res. 2017;77:494–59.

60. Sun J, Feng Y, Wang Y, Ji Q, Cai G, Shi L, et al. a-hederin induces autophagic cell death in colorectal cancer cells through reactive oxygen species dependent AMPK/mTOR signaling pathway activation. Int J Oncol. 2019;54:1601–12.

61. Han M, Hu J, Lu P, Cao H, Yu C, Li X, et al. Exosome-transmitted miR-577 reverses trastuzumab resistance by inhibiting ATGS in breast cancer. Cell Death Dis. 2020;11:43. https://doi.org/10.1038/s41419-020-2250-5.

62. Ahmed S, Saffan M, Modarresi MH, Shirkoohi R, Jamalian M, Teimori H. Dysregulation of miR-638 in breast cancer patients and bioinformatics investigation of its target genes in apoptosis, angiogenesis and autophagy pathways. Int J Cancer Manag. 2019;12:88829.

63. Frankel LB, Wen J, Lees M, Hayer-Hansen M, Farkas T, Kohg A, et al. MicroRNA-101 is a potent inhibitor of autophagy. EMBO J. 2011;30:4628–41.

64. Ren Y, Chen Y, Liang X, Lu Y, Pan W, Yang M. MiRNA-683 promotes autophagy and malignant phenotypes of cancer cells via directly suppressing DACT3. Cancer Lett. 2017;390:126–36.

65. Ueda S, Takanashi M, Sudo K, Kanekura K, Kuroda M. miR-27a ameliorates tumor growth inhibition and chemotherapy resistance by targeting the PI3K/AKT/mTOR pathway. Oncotarget. 2014;5:7013–26.

66. Li F, Miao L, Xue T, Qin H, Mondal S, Thompson PR, et al. Inhibiting PAD2 enhances the anti-tumor effect of docetaxel in tamoxifen-resistant breast cancer cells. J Exp Clin Cancer Res. 2019;38:414.

67. Ruiz Espanar-Gamido R, Torres-Márquez ME, Viedma-Rodríguez R, Velázquez-Wong AC, Salamanca-Cómez F, Rosas-Vargas H, et al. Breast cancer cell line MDA-MB-231 miRNA profile expression after BIK interference: BIK involvement in autophagy. Tumor Biol. 2016;37:6749–59. https://doi.org/10.1007/s13277-015-4494-8.

68. Wang Z, Wang N, Liu P, Chen Q, Situ H, Xie T, et al. MicroRNA-25 regulates chemoresistance-associated autophagy in breast cancer cells, a process modulated by the natural autophagy inducer 1,2-oleoylglycerol. Oncotarget. 2014;5:7013–26.

69. Liang G, Ling Y, Melpourp M, Saw PE, Liu Z, Tan W, et al. Autophagy-associated circRNA circCDYL augments autophagy and promotes breast cancer progression. Mol Cancer Molecular Cancer. 2020;19:65.
86. Wu Q, Li J, Li Z, Sun S, Zhu S, Wang L, et al. Exosomes from the tumour-adipocyte interplay stimulate beige/brown differentiation and reprogram metabolism in stromal adipocytes to promote tumour progression. J Exp Clin Cancer Res. 2019;38:223.

87. Moruno F, Pérez-Jiménez E, Knecht E. Regulation of autophagy by glucose in mammalian cells. Cells. 2012;1:372–95.

88. Wang Y, Li P, Wang S, Hu J, Chen XA, Wu J, et al. Anticancer peptidyl-larginine deiminase (PAD) inhibitors regulate the autophagy flux and the mammalian target of rapamycin complex 1 activity. J Biol Chem. 2012;287:25941–53.

89. Singh B, Reddy PG, Goberdhan A, Walsh C, Diao S, Ngai I, et al. p53 regulates cell survival by inhibiting PI3K/Akt in squamous cell carcinomas. Genes Dev. 2002;16:984–93.

90. Tang D, Kang R, Livesey KM, Cheh CW, Farkas A, Loughran P, et al. Endogenous HMGB1 regulates autophagy. J Cell Biol. 2010;190:881–92.

91. Lu T, Zhu Z, Wu J, She H, Han R, Xu H, et al. DRAM1 regulates autophagy and cell proliferation via inhibition of the phosphoinositide 3-kinase-Akt-mTOR-ribosomal protein S6 pathway. Cell Commun Signal. 2019;7:28.

92. Meng C, Liu Y, Shen Y, Liu S, Wang Z, Ye Q, et al. MicroRNA-26b suppresses autophagy in breast cancer cells by targeting DRAM1 mRNA, and is downregulated by irradiation. Oncol Lett. 2018;15:1435–40.

93. Sun Q, Liu T, Yuan Y, Guo Z, Xie G, Du S, et al. MiR-200c inhibits autophagy and enhances radiosensitivity in breast cancer cells by targeting UBQLN1. Int J Cancer. 2015;136:1003–12.

94. Lee DY, Arnett D, Brown EJ. Ubiquilin4 is an adaptor protein that recruits Ubiquilin1 to the autophagy machinery. EMBO Rep. 2013;14:373–81. https://doi.org/10.1038/embor.2013.22.

95. Cheung CHA, Chang YC, Lin TY, Cheng SM, Leung E. Anti-apoptotic proteins in the autophagic world: an update on functions of XIAP, Survivin, and BRUCE. J Biomed Sci. 2020;27:31.

96. Chen P, He Y-H, Huang X, Tao S-Q, Wang X-N, Yan H, et al. MiR-23a modulates X-linked inhibitor of apoptosis-mediated autophagy in human luminal breast cancer cell lines. Oncotarget. 2017;8:80709–21.

97. Chen M, Chen Z, Wang Y, Tan Z, Zhu C, Li Y, et al. Mitophagy receptor FUNDC1 regulates mitochondrial dynamics and mitophagy. Autophagy. 2016;12:689–702. https://doi.org/10.1080/15548627.2016.1151580.

98. Xu G, Shen H, Nibona E, Wu K, Ke X, Al Hafiz MA, et al. Fundc1 is necessary for proper body axis formation during embryogenesis in zebrafish. Sci Rep. 2019;9:18910.

99. Hu Q, Yuan Y, Wu Y, Huang Y, Zhao Z, Xiao C. MicroRNA-137 exerts protective effects on hypoxia-induced cell injury by inhibiting autophagy/mitophagy and maintaining mitochondrial function in breast cancer stem-like cells. Oncol Rep. 2020;44:1627–37.

100. Hao Y, Baker D, Dijke P, Ten. TGF-β-mediated epithelial-mesenchymal transition and cancer metastasis. Int J Mol Sci. 2019;20:2767.

101. Cheng Y, Li Z, Xie J, Wang P, Zhu J, Li Y, et al. MiRNA-224-5p inhibits autophagy in breast cancer cells via targeting smad4. Biochem Biophys Res Commun. 2018;506:793–8.

102. Sharma P, Singh S. Combinatorial effect of DCA and Let-7a on triple-negative MDA-MB-231 cells: a metabolic approach of treatment. Integr Cancer Ther. 2020;19:1–11.

103. Wang J, Xie S, Yang J, Xiong H, Jia Y, Zhou Y, et al. The long noncoding RNA H19 promotes tamoxifen resistance in breast cancer via autophagy. J Hematol Oncol. 2019;12:81.

104. Lan H, Lu H, Wang X, Jin H. MicroRNAs as potential biomarkers in cancer: opportunities and challenges. Biomed Res Int. 2015;2015:125094.

105. Saliminejad K, Khoshid HR, Ghaffari SH. Why have microRNA biomarkers not been translated from bench to clinic? Futur Oncol. 2019;15:801–3.

106. Segal M, Slack FJ. Challenges identifying efficacious miRNA therapeutics for cancer. Expert Opin Drug Discov. 2020;15:987–92. https://doi.org/10.1080/17460441.2020.1765770.

Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.